Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: DRUG: AZD9833|DRUG: AZD9833|DRUG: AZD9833 with palbociclib|DRUG: AZD9833 with palbociclib|DRUG: AZD9833 with everolimus|DRUG: AZD9833 with everolimus|DRUG: AZD9833 with abemaciclib|DRUG: AZD9833 with abemaciclib|DRUG: AZD9833 with capivasertib|DRUG: AZD9833 with capivasertib|DRUG: AZD9833 with ribociclib|DRUG: AZD9833 with ribociclib|DRUG: AZD9833 with anastrozole|DRUG: AZD9833 with anastrozole
Sponsor: AstraZeneca